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SUMMARY
1. Tissue plasminogen activator (tPA) has both fibrinolytic
and anti-inflammatory activity. These properties may be useful
in treating inflammatory lung diseases, such as acute respiratory
distress syndrome (ARDS).
2. We have previously demonstrated the feasibility of targeted
pulmonary delivery of tPA. As part of our research to develop
a clinically viable pulmonary formulation of tPA, we assessed
the tolerability and incidence of haemorrhage associated with
the administration of a pulmonary formulation of mouse tPA
(pf-mtPA).
3. Intratracheal doses of nebulized pf-mtPA or sterile saline
were administered with increasing frequency to male and female
B6C3F1 mice. After dosing, the mice entered a recovery period,
after which they were killed and their lungs were lavaged and
harvested. Post-mortem gross necropsy was performed and all
major organs were assessed histologically for haemorrhage. The
bronchoalveolar lavage fluid was assessed for markers of lung
injury.
4. Mouse tPA that was formulated to mimic a previously
characterized human pf-tPA was well tolerated when given intra-
tracheally with increasing dosing frequency. The administration
of pf-mtPA did not result in any detectable haemorrhagic-related
events or signs of lung injury.
5. The results of the present longitudinal study demonstrate
that a maximally feasible dose of pf-mtPA (3 mg/kg) can be given
frequently over a short period of time (12 h) without haemor-
rhagic complications. Although these data were generated in a
healthy mouse model, they provide support for the continued
evaluation of pf-tPA for the treatment of pulmonary diseases,
such as ARDS.
Key words: B6C3F1 mice, haemorrhage, nebulization,
pulmonary drug delivery, tissue plasminogen activator.
INTRODUCTION
Tissue plasminogen activator (tPA) is an endogenous serine protease
responsible for fibrin degradation via the activation of plasminogen.
Clinically, this function of tPA has been exploited for use in the
treatment of myocardial infarction (MI) and thrombotic stroke. More
recently, however, mounting evidence suggests that tPA participates
in a number of physiological functions that are independent of its
fibrinolytic activity.1–4 In particular, we have demonstrated the ability
of exogenous tPA to suppress activator-induced superoxide anion
production by professional phagocytes and to reduce injury in animal
models of acute inflammation.5–8 Both the fibrinolytic and anti-
inflammatory properties of tPA could be of use in the treatment of
acute respiratory distress syndrome (ARDS), because this illness is
characterized by neutrophil-mediated oxidant stress and fibrin
deposition in the lungs.9,10
We have previously demonstrated the feasibility of a pulmonary
formulation of human tPA (pf-tPA).11 Targeted pulmonary delivery
of tPA would permit direct therapy to the site of drug action and
would avoid systemic administration of tPA, which may put patients
at undue risk of adverse bleeding events.12,13 Haemorrhage is the
most serious toxicity of tPA. However, pulmonary delivery of pf-tPA
may not be free of bleeding risk, particularly because, unlike in
the treatment of MI or stroke, the anticipated clinical situation would
require repeated administration. Importantly, to fully assess the
tolerability and haemorrhagic potential of pf-tPA, the use of species-
specific tPA is required because human tPA varies in its ability to
activate various animal plasminogen.14
Therefore, the purpose of the present study was to test the toler-
ability of a maximally feasible dose (3 mg/kg) of mouse pf-tPA (pf-
mtPA) when given with accelerated frequency to mice. The human
pf-tPA formulation parameters established in our previous study were
used as benchmarks for the formulation of pf-mtPA.11 Several
end-points were measured to assess tolerance, the occurrence of
haemorrhage and/or lung injury in B6C3F1 mice treated with either
placebo or nebulized pf-mtPA administered via intratracheal instillation.
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METHODS
Mouse tPA
Recombinant mouse tPA (mtPA; Molecular Innovations, Southfield, MI, USA)
was formulated to mimic a pulmonary formulation of human recombinant tPA,
as described previously.11
Assessment of pf-mtPA stability and function
Protein concentration was assessed by ultraviolet (UV) spectroscopy (HP8453
spectrophotometer; Agilent Technologies, Palo Alto, CA, USA). To determine
whether nebulization of pf-mtPA provoked protein self-association, an aggre-
gation index (AI) of pre- and post-nebulized pf-mtPA was determined.11,15 The
AI was calculated using the following equation:
AI = 100 × LS280/(Abs280 – LS280)
where LS280 is the light scattering absorbance (Abs) at 280 nm determined by
linear regression extrapolation through 340, 370 and 400 nm. Measurement
of self-association is important because the presence of aggregates (e.g.
AI > 10) may contribute to an immune response to the protein.11,16
Plasminogen activator inhibitor-1 (PAI-1) is the physiological inhibitor of
tPA.17 The binding of tPA to PAI-1 is a very specific and high-affinity inter-
action that results in the complete suppression of the proteolytic activity of
tPA, which is responsible for the conversion of plasminogen to plasmin.18,19
To test whether the formulation process disrupted the activity of pf-mtPA,
pf-mtPA–PAI binding studies were performed using a stable mutant form of
human PAI-1 (CPAI) containing four mutations (K154T, Q319L, M354I and
N150H; Molecular Innovations). These mutations confer stability to the
otherwise labile serpin protein, essentially locking it into its active conformation.
Mouse tPA protein (5 g) was incubated in the presence or absence of CPAI
(15 g) in Tris-buffered saline (TBS; ×1) at room temperature for 1 min to
1 h. Each reaction was stopped by the addition of bioanalyser sample buffer
(Agilent Technologies, Santa Clara, CA, USA) and heating to 70°C for 10 min.
Each denatured sample was then diluted to a final volume of 90 L with water.
Samples were assayed and analysed by an Agilent 2100 bioanalyser according
to the Protein 200 Plus (Agilent Technologies) assay protocol. This approach
uses lab-on-a-chip technology to quantify protein–protein interactions and has
been shown to be comparable in sensitivity to sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS-PAGE).20 Data were analysed
using the bioanalyser software.
The fibrinolytic activity of nebulized pf-mtPA was assessed by measuring
the cleavage of mouse plasminogen to plasmin.11 Each pf-mtPA sample was
incubated with mouse plasminogen (375 g/mL; Molecular Innovations) for
5 h (37°C) in a reaction volume of 50 L. Following incubation, the protein
was separated by 10% SDS-PAGE and protein bands were visualized by
Coomasie blue.
Nebulization and dose preparation
The liquid formulation of pf-mtPA was jet nebulized using a Micromist
nebulizer (Hudson Respiratory Care, Temecula, CA, USA) with a Sunrise
compressor (Model 3655D; Somerset, PA, USA). The collected aerosol was
assayed for protein concentration and the AI of pre- and post-nebulized
pf-mtPA was determined by UV spectroscopy.11 The aerosolization of tPA
formulated for pulmonary delivery results in the production of particles with
a mass mean diameter and geometric standard deviation of 2.4 m and 2.7 m,
respectively, which is suitable for delivery to the lower airways. This produces
a respirable dose of at least 65%.11 The fibrinolytic activity of pf-mtPA was
assessed by measuring the cleavage of plasminogen to plasmin, as described
above.
Single dose (approximately 80 L) aliquots of nebulized pf-mtPA were
stored at 4°C for no more than 1 week. Before use, the protein concentration
and AI of stored pf-mtPA were measured. Additional pf-mtPA was nebulized
as needed. At the time of dosing, the required volume of pf-mtPA or sterile
saline was drawn into a sterile syringe (1 mL) to which a gavage needle (22 G;
Hallowell EMC, Pittsfield, MA, USA) was attached. The syringe was prepared
so that approximately 100 L air followed the dose.
Animal studies
The animal protocol was approved by the University of Colorado Health
Sciences Center Animal Care and Use Committee and the research adhered
to the Principles of Laboratory Animal Care (http://grants.nih.gov/grants/
olaw/references/phspol.htm).
Mice (B6C3F1) were purchased from Taconic Farms (Hudson, NY, USA).
Male and female mice (8–9 weeks old) received either a single intratracheal
instillation of pf-mtPA (3 mg/kg) or one dose every 2 h for 4, 8 or 12 h. An
equivalent volume of sterile saline (placebo) was given to control mice using
the same dosing scheme. Four to six mice were assigned to each group. For
dose administration, each mouse was anaesthetized under isoflurane (IsoFlo;
isoflurane, USP; Abbott Animal Health, North Chicago, IL, USA), after which
the vocal cords were visualized using a rodent intubation table (Hallowell
EMC) and a paediatric otoscope (Welch-Allyn Medical Products, Skaneateles
Falls, NY, USA). The tip of the gavage needle was gently moved past the vocal
cords and into the trachea; the dose of either pf-mtPA or sterile saline was
delivered by depression of the syringe’s plunger. Following drug or saline
administration, the mouse was held upright for approximately 5 s, after which
the mouse was returned to the cage and allowed to recover from anaesthesia.
Upon the completion of the dosing scheme, animals entered a 2 week recovery
period that allowed for the longitudinal assessment of each animal. Because
haemorrhage associated with tPA administration is most often acute and
symptomatic (e.g. stroke, gastrointestinal), animals were observed twice
daily for changes in behaviour and/or function that could be associated with
morbidity.12,13,21,22 Specifically, lack of grooming, a decline in food and water
consumption or urine/faecal production, lethargy or signs of neurological deficit
were documented. Respiratory difficulty or distress was considered a study
end-point. Nutritional status and well-being were also assessed by changes in
weight, for which animals were weighed prior to dosing and on Days 3, 7 and
14. In order to detect haemorrhage in the absence of signs and to account for
the possibility of slow, prolonged or asymptomatic bleeding, estimated hae-
matocrit was measured just prior to dosing and at the conclusion of the study.
Blood (50 L) was acquired from the retro-orbital sinus by carefully inserting
a heparinized capillary tube into the medial canthus at a 30° angle to the nose
while the animal was under isoflurane anaesthesia and a local anaesthetic
(proparacaine). Following blood acquisition, pressure was gently applied to
the site to ensure the cessation of blood flow before returning the mouse to
the cage. Packed red blood cell volume was used as an estimate of haematocrit
by subjecting the blood-filled capillary tube to centrifugation and measuring
the packed red cell volume as a percentage of the total sample volume.
At the conclusion of the recovery period, mice were killed and their lungs
lavaged twice each with 400 L sterile phosphate-buffered saline (PBS). The
two broncheoalveolar lavage fluid (BALF) samples were pooled and a cell
count was performed using a haemacytometer; a cell differential was per-
formed by fluorescence-activated cell sorting (FACS). The BALF was assayed
for protein and lactate dehydrogenase (LDH) activity as indicators of lung
injury.23,24 Following thoracotomy, the lungs were perfused blood-free with
buffered formalin (10%) via catheterization of the right ventricle. Subse-
quently, all animals were perfused blood-free with buffered formalin, after
which they were subjected to gross necropsy by a veterinarian blinded to treat-
ment group assignment. Following gross necropsy, the major organs were
harvested and paraffin embedded. A single 5 m section from each sample
was acquired and stained with haematoxylin and eosin for microscopic histo-
logical evaluation. Paraffin embedding, sectioning and staining of organs were
performed by the University of Colorado Histology Core Laboratory.
Because the lungs contain endogenous tPA, to characterize the distribution
of tPA protein in the lungs following intratracheal administration, mice (n = 3)
received a single dose (3 mg/kg) of nebulized human pf-tPA or a matching
volume of sterile saline (n = 1). Immediately following dose administration,
animals were killed and the lungs harvested without lavage. The superior left
lobe (which comprises approximately 98% of the left lung mass) was separated
from the inferior left lobe and the three right lobes were separated into the
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superior, mid and inferior lobes. Each lobe from each animal was placed in
separate tubes on ice and each was homogenized as described previously.25
Each lung lobe homogenate was assayed for human tPA protein concentration
by a 96-well microtitre plate enzyme-linked immunosorbent assay. This assay
measured total tPA by using a tPA capture antibody (rabbit anti-human tPA;
Molecular Innovations) and a different detection antibody (mouse anti-human;
CalBiochem, Gibbstown, NJ, USA). The tPA protein was detected following
the addition of a secondary antibody (mouse IgG HRP; Millipore, Baillerica,
MA, USA) that was quantified by determining the optical density of each well
at 450 nm (SpectraMax Plus; Molecular Devices, Sunnyvale, CA, USA). The
tPA concentration in each well was determined from the standard curve by
plate reader software. To estimate lung distribution, measured concentrations
in each lobe were normalized to 1 mL, from which the amount of protein was
determined. The percentage of tPA in each lobe was calculated by dividing
this value by total delivered tPA protein and multiplying it by 100.
Differentiation of BALF cells by FACS
To determine the percentage of leucocytes (neutrophils, macrophages, lym-
phocytes) in each BALF sample, cells were pelleted by centrifugation
(10 000 g, 4°C, 5 min) and resuspended in goat serum (2%) in a Krebs’–
Ringer–phosphate–dextrose buffer for 1 h. Cells were then pelleted again and
resuspended in 100 L staining buffer (1% bovine serum albumin in PBS) to
which the following stains were added: F480 PE (Cal Tag, Burlingame, CA,
USA), rat anti-mouse neutrophil–fluorescein isothiocyanate (Cal Tag), anti-
CD45 PE-Cy7 (BD Bioscience, San Jose, CA, USA), anti-CD3 APC (BD Bio-
science), anti-CD45/B220 APC (BD Bioscience) and Live/Dead Fixable Red
Dead Cell stain (Invitrogen, Carlsbad, CA, USA). Cells were stained for
20 min at room temperature. Following staining, cells were washed in staining
buffer and fluorescence was detected by a Cytomics FC500 (Beckman Coulter,
Fullerton, CA, USA) at the University of Colorado Cancer Center Flow
Cytometry Core Laboratory.
Determination of BALF protein concentration and 
LDH activity
Protein levels were determined using a micro bicinchoninic acid (BCA) protein
assay (Pierce, Rockford, IL, USA).26 This assay uses an extended incubation
time at an elevated temperature (60°C), which results in a very sensitive
colourimetric protein assay. Leakage of intracellular LDH was measured using
an activity assay kit (Sigma-Aldrich, St Louis, MO, USA). Briefly, clarified
BALF supernatant (100 L) was added to Reagent A (2.5 mL) for 1 min, fol-
lowed by the addition of Reagent B (100 L). The rate of decrease in absorb-
ance (340 nm) recorded every minute for 3 min is indicative of the reduction
of pyruvate to lactate coupled to the oxidation of NADH to NAD.27 Absorbance
data were analysed using Softmax PRO 4.1 on a ThermoMax microplate reader
(Molecular Devices). Lactate dehydrogenase activity data are represented as
NADH consumed (U/mL).
Data analysis
Data were analysed by anova (or a two-tailed Student’s t-test, when applica-
ble) using StatView (SAS, Cary, NC, USA). A Fisher protected least significant
difference post hoc analysis was performed where appropriate. In all cases,
P ≤ 0.05 was considered significant.
RESULTS
The pf-mtPA was proteolytically active, as determined by pf-mtPA–
CPAI binding studies. The protein was primarily single-chain (approx-
imately 85%), as evidenced by a 67 kDa single peak at 28 s (Fig. 1a).
Most (89%) of the CPAI migrated at 24.5 s with a molecular weight
of 38 kDa (Fig. 1b). The incubation of pf-mtPA with CPAI resulted
in the formation of an mtPA–CPAI complex, in which 46% of the
mtPA was bound to CPAI (Fig. 1c). These results are consistent with
the manufacturer’s characterization of purified mtPA and CPAI
(Fig. 1d). Incubation time (1 min to 1 h) did not influence mtPA–CPAI
complex formation or bioanalyser results and these data were consistent
with those observed by SDS-PAGE (Fig. 1d).
In preparation for animal testing, pf-mtPA (1 mg/mL) was neb-
ulized and protein was assessed for stability and activity. Nebulization
did not result in an AI > 10, which is consistent with the feasibility
criteria established in earlier work (Table 1).11 In addition, following
nebulization, pf-mtPA retained its fibrinolytic activity (Fig. 2) and the
protein concentration and AI of stored (4°C) nebulized pf-mtPA
remained stable (Table 1).
Animal testing
All animals survived the dosing and recovery periods. The mean
(±SEM) age of male and female mice were similar (9.47 ± 0.17 and
9.63 ± 0.16 weeks, respectively; P = 0.48), regardless of treatment.
There were no detected treatment-related or dosing frequency related
haemorrhagic events. There was also no evidence of failure-to-thrive
or neurological deficit because there were no apparent changes in
animal behaviour or weight.
The administration of both pf-mtPA and placebo was well tolerated.
In female mice that received six doses of intratracheal pf-mtPA the
mean (±SEM) estimated haematocrit decreased from a pretreatment
value of 53.5 ± 0.6% to a post-treatment value of 46.5 ± 0.6%
(P = 0.003, Student’s t-test). However, a similar drop in mean hae-
matocrit also occurred in female intratracheal placebo (×6)-treated
mice. Male mice that received either intratracheal pf-mtPA (×6) or
intratracheal placebo (×6) did not have significant pre- or post-
treatment changes in mean (±SEM) haematocrit (intratracheal pf-mtPA
(×6): 50.0 ± 0.8% to 44.5 ± 3.5% (P = 0.137); intratracheal placebo
(×6): 50.5 ± 0.3% to 49.7 ± 0.7% (P = 0.423)). However, one male
mouse treated with intratracheal pf-mtPA (×6) experienced a greater
decline in haematocrit (from 50% to 37%) than any of the other mice
in the group. This is unexplained because this animal did not have
any clinical or pathological evidence of haemorrhage and blood
sampling was infrequent, so it is not likely to be the cause. In fact,
there was no clinical evidence of haemorrhagic events and conclusive
signs of haemorrhage were not identified by gross necropsy in any of
the animals. In addition, microscopic assessment of the vitals organs
(brain, lungs, heart, liver and kidneys) did not reveal any findings of
haemorrhage. Nevertheless, all female mice treated with either six
doses of intratracheal pf-mtPA or intratracheal placebo experienced a
decline in haematocrit. This decline in haematocrit was only observed
in female mice that received six doses of either intratracheal pf-mtPA
or intratracheal placebo. In the absence of any signs or pathological
evidence of bleeding, this observation may be due to the smaller body
mass of the female mice compared with their male counterparts. On
average, female mice weighed 20% less than male mice. The lower
bodyweight and corresponding smaller blood volume may have made
them more susceptible to a reduction in estimated haematocrit
secondary to repeated blood collection despite the use of a conservative
blood sampling scheme to attempt to minimize this possibility.
All animals maintained a stable weight during the study period.
However, female mice gained less weight over time than male mice.
The mean (±SEM) weight gain for female intratracheal placebo (×6)
and intratracheal pf-mtPA (×6) mice was 1.2 ± 0.2 and 1.6 ± 0.3 g,
respectively, whereas intratracheal placebo (×6) and intratracheal
pf-mtPA (×6)-treated male mice gained 2.5 ± 0.4 and 2.3 ± 0.4 g,
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Fig. 1 Representative electropherograms of bioanalyser data of a pulmonary formulation of mouse tissue plasminogen activator (pf-mtPA) and interactions
between pf-mtPA and a stable mutant form of human plasminogen activator inhibitor-1 (CPAI) at pH 7.3. (a) Analysis of pf-mtPA produced an electropherogram
in which most of the protein (85%) migrated at 28 s (peak 5). (b) Analysis of CPAI. The two smaller peaks (3 and 5) comprise approximately 10% of the total
protein and may be contaminants or by-products. (c) Analysis of pf-mtPA in the presence of CPAI for 1 h at room temperature produced four peaks (4–7). The
mtPA–CPAI complex is represented by peak 7 at 30–31 s (98 kDa). (d) Activity and purity of mtPA by 10% sodium dodecyl sulphate–polyacrylamide gel
electrophoresis following GelCode Stain. Lane 1, CPAI (15 g); lane 2, CPAI (15 g) and mtPA (5 g) resulted in a bound CPAI–mtPA complex (~100 kDa);
lane 3, mtPA (5 g); lane 4, molecular weight marker (figure provided by Molecular Innovations).
Table 1 Storage (at 4°C) did not alter the protein concentration or aggregation
index of the pulmonary formulation of mouse tissue plasminogen activator
(pf-mtPA)
Condition pf-mtPA (mg/mL) Aggregation index
Prenebulized 1.10 ± 0.00 1.28 ± 0.04
Freshly nebulized 1.21 ± 0.01 1.58 ± 0.34
Post-nebulization (48 h) 1.19 ± 0.00 2.89 ± 1.50
Post-nebulization (1 week) 1.21† 1.56†
Data are the mean±SEM from at least three samples, except for those
indicated by the dagger (†), which are for a single sample.
Fig. 2 Nebulization and storage did not alter fibrinolytic activity of a pulmo-
nary formulation of mouse tissue plasminogen activator (pf-mtPA). Represent-
ative sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE)
gel (10%) showing fibrinolytic activity of pf-mtPA (lane 1, 50 g/mL; lane 2,
100 g/mL; lane 3, 250 g/mL) just after nebulization (a) or after 1 week of
storage at 4°C (b) following incubation with mouse plasminogen (375 g/mL)
for 5 h (37°C). Samples were subjected to SDS-PAGE along with mouse plas-
minogen and plasmin and molecular weight markers (MWM) for protein iden-
tification and size determination. Protein band density is less in (b) than in (a)
because less protein was loaded.
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respectively. This is most likely related to sex because age-related
differences did not account for this observation.
Tissue plasminogen activator protein was detected throughout the
lungs following a single intratracheal dose of nebulized human pf-tPA
(Fig. 3). Approximately 20% of the delivered protein reached
the lower lobes of the lungs. There was no detectable human tPA
in the plasma samples collected. Given the diffuse and distal distri-
bution of tPA, it is reasonable to assume that, consistent with our
previous data, some particles reached the alveoli whereas some
remained in the larger airways. Regardless, there was no evidence
of haemorrhage in either the parenchyma or the larger airway tissues
by histology.
Neither pf-mtPA treatment nor increasing dosing frequency
resulted in lung inflammation or injury compared with intratracheal
placebo, as evidenced by a lack of difference in BALF cell counts
(Fig. 4), protein (Fig. 5) and LDH activity between pf-mtPA- and
placebo-treated mice. These results demonstrate that intratracheal
administration of pf-mtPA given up to six times over a 12 h period
was well tolerated by the lungs. However, regardless of treatment and
dosing frequency, the mean BALF cell concentration was higher in
male mice than in female mice (Fig. 4). This is most likely sex related
because sex differences in mouse pulmonary function and response
have been described previously.28 Specifically, male mice have been
shown to have a more profound inflammatory response to oropharyn-
geal aspiration of lipopolysaccharide (LPS), as evidenced by higher
BALF inflammatory cell counts.28 Furthermore, there is also strain
variation in both pulmonary function and pulmonary inflammatory
responses.29,30 Notably, in the present study, the intratracheal admin-
istration of pf-mtPA was not associated with an inflammatory response
regardless of dosing frequency. Comparatively, untreated male mice
Fig. 3 Distribution of tissue plasminogen activator protein in the lobes of
mouse lungs following a single intratracheal dose (3 mg/kg) of a nebulized
pulmonary formulation of human tissue plasminogen activator (pf-tPA). SL,
superior left lobe; IL, inferior left lobe; SR, superior right lobe; MR, mid-right
lobe; IR, inferior right lobe. Data are the mean±SEM from three mice.
Fig. 4 Increasing dosing frequency of (a) female and (b) male mice with
either intratracheally administered placebo () or a pulmonary formulation of
mouse tissue plasminogen activator (pf-mtPA; ) was not associated with
changes in broncheoalveolar lavage (BALF) cell concentration or inflamma-
tory cell differential. Female mice (a) had consistently lower BALF cell con-
centrations than male mice (b), regardless of treatment (pf-mtPA vs placebo)
or dosing frequency (P < 0.0001). There were no differences between pf-mtPA-
and placebo-treated male and female mice and most cells in all groups were
macrophages (see text). Data are the mean±SEM of four to six mice per group.
Fig. 5 Increasing dosing frequency of (a) female and (b) male mice with either
intratracheal placebo () or a pulmonary formulation of mouse tissue plasmino-
gen activator (pf-mtPA; ) was not associated with changes in broncheoalveolar
lavage fluid (BALF) protein concentration, as determined by the BCA assay.
Female mice (a) had lower BALF protein concentrations compared with male
mice (b) regardless of treatment (pf-mtPA vs placebo) or dosing frequency
(P = 0.0114). These results are consistent with those shown in Fig. 4 because
male mice have a more pronounced pulmonary response to intratracheal
administration (see text). Data are the mean±SEM of four to six mice per group.
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(n = 4) that were not subjected to intratracheal instrumentation had a
mean (±SEM) BALF cell concentration of 18.4 ± 3.0 × 104 cells/mL
that was not different from any BALF concentration other than the
placebo and tPA (×4) male mice (P = 0.005; Fig. 4b). In addition,
these cells were mostly macrophages (82.8 ± 2.7%). Most of the cells
(≥ 80%) in the BALF in male and female mice treated with either tPA
or placebo were macrophages, regardless of dosing frequency (data
not shown). These data suggest that there is no reason to conclude
that intratracheal administration of pf-mtPA results in an inflammatory
response in the lungs.
The sex difference was also apparent in measured BALF BCA
protein concentration. Male mice, regardless of treatment or dosing
frequency, had higher BALF protein concentration compared with
female mice (Fig. 5). However, LDH activity was below the level of
detection (< 0.04 U/mL) in all samples, regardless of sex, treatment
or dosing frequency (data not shown), providing evidence that intrat-
racheal administration of pf-tPA was not associated with lung injury.
Collectively, the BALF data support the concept that intratracheal
administration of pf-mtPA was well tolerated and was not associated
with an increase in measured markers of lung inflammation or injury.
DISCUSSION
The present study demonstrated the tolerability of a pulmonary for-
mulation of mouse tPA when given with increasing frequency. The
significance of this study is that it provides evidence for the safety of
the pulmonary route of delivery for a new and novel formulation of
tPA. The use of a species-specific therapeutic protein formulation is
particularly important for the accurate assessment of tPA toxicity
because there is species variation in the tPA substrate plasminogen.14
In addition, species-specific therapeutic protein formulations that
imitate the human product could assist in addressing the growing need
for animal models of drug–disease interactions that can assist in pre-
dicting successful translation of preclinical data to safety and efficacy
in the clinical situation.
In the mouse model used in the present study, we tested a maximally
feasible dose (3 mg/kg) of pf-mtPA, given with ascending dosing
frequency. The maximally feasible dose was determined based on the
amount (volume) of drug that could reasonably be administered as a
single dose (approximately 80 L). This approach was used in order
to characterize the ‘worse case’ clinical scenario, which would be the
frequent administration of a higher than expected dose. Despite an
aggressive dosing frequency of every 2 h and the administration of
up to six doses over a period of 12 h, none of the animals experienced
an acute haemorrhagic event (e.g. stroke) or respiratory complications
during the dosing period. There were also no apparent late systemic
or pulmonary haemorrhagic consequences, as evidenced by a lack of
change in estimated haematocrit during the recovery phase and the
results of gross necropsy and histological assessment of target organs.
However, we acknowledge that our ability to assess asymptomatic
bleeding during the recovery may have been limited by a conservative
blood sampling scheme (≤ 100 L over 14 days), which we used to
try to reduce the likelihood of anaemia secondary to blood sampling.
Despite this, if physiologically relevant bleeding occurred, we would
expect it to have been detected by either gross necropsy or histology,
which it was not. Furthermore, none of the animals demonstrated signs
consistent with bleeding, such as respiratory distress, neurological
deficit or failure-to-thrive, changes in grooming, a decline in food and
water consumption or urine/faecal production, lethargy or weight loss.
The purpose of developing a pulmonary formulation of tPA is to
circumvent the systemic circulation and allow for targeted pulmonary
delivery of tPA to the site of drug action. Our previous work has
demonstrated that nebulization of a pulmonary formulation of tPA
produced particles that can feasibly reach the lower airways.11 Given
our objective to target treatment to the lungs, it would be preferably
that lung-delivered tPA not reach the systemic circulation. Impor-
tantly, for protein therapeutics, particle size alone does not predict
systemic delivery; there are a number of other variables that contribute.31
These include protein size, hydrophobicity and cellular uptake or tissue
binding. Furthermore, route of administration (in the case of the
present study, intratracheal administration of nebulized protein, which
involves pushing drug into the airways using a syringe) will also influ-
ence particle distribution in the lungs. Nevertheless, this approach did
result in diffuse distribution of the protein in the lungs, with approx-
imately 20% of protein reaching the lower lungs.
Although the present study was not designed to evaluate the sys-
temic absorption of pulmonary delivered tPA, tPA was not detected
in plasma samples collected following a single dose of nebulized
human pf-tPA. Thus, our results suggest that pulmonary administration
of pf-mtPA, an approximately 68 kDa protein, did not cause a sufficient
increase in systemic mtPA concentration to provoke bleeding. It is
important to recognize that because we did not measure systemic
mtPA concentrations or fibrinolytic activity in the blood following
multiple doses or over time, it is possible that both increased without
the occurrence of bleeding. Previous work by others in pigs showed
that, following traumatic injury, the single administration of nebulized
recombinant single chain urokinase (UK; approximately 5.7 mg/kg)
was associated with a transient but small increase in systemic UK
concentration but did not result in a detectable increase in systemic
fibrinolytic activity.32 Because the purpose of our study was to test
the tolerability of pf-mtPA, a separate study is underway to determine
the pharmacokinetics of lung-delivered pf-tPA, in which a compre-
hensive assessment of the pulmonary to plasma distribution of pf-tPA
will be made.
We chose to administer nebulized pf-mtPA intratracheally. Unfor-
tunately, there is no optimal or ideal model of experimental pulmonary
drug delivery. The advantages of intratracheal administration are
conservation of material and more precise dosing because the drug is
delivered directly into the airway. Alternatively, aersolization of drug
into a chamber results in inconsistent delivery of drug into the lungs
owing to variability in breathing patterns and the proximity of animals
to the aerosol emission site. Furthermore, mice are nose breathers, so
chamber inhalation results in a significant amount of drug deposition
into their nasal passages, as well as significant animal-to-animal
variability in the amount of drug that enters the deep lungs. Our work
and that by others has demonstrated that intratracheal administration
results in efficient delivery of liquid to the distal lungs.33 Therefore,
these data, coupled with previous data that characterized pf-tPA airway
distribution, are representative of the anticipated clinical results
following the nebulization of human pf-tPA into normal human lungs.
We conducted our experiments in B6C3F1 mice. This is a first gen-
eration (F1) hybrid strain produced by crossing C57BL/6 females with
C3H males. The advantage of an F1 hybrid is genetic and phenotypic
uniformity that minimizes animal-to-animal variability. In addition,
this strain is frequently used for a broad range of toxicological and
pharmacological studies.34–36 These were, however, healthy mice with
normal lungs. In the expected clinical situation of ARDS, for example,
the lungs would be inflamed with an associated increase in vascular
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permeability. Therefore, no conclusions can be made about the poten-
tial haemorrhagic risk that may be present following pulmonary
administration of pf-tPA in diseased lungs. Planned future work is
directed at assessing efficacy and toxicological end-points in a mouse
model of lung inflammation.
In conclusion, the results of the present study demonstrate that a
high dose of a pulmonary formulation of mtPA that mimics the human
pulmonary formulation of tPA can be given with increasing frequency
without causing systemic or lung haemorrhage or lung injury. Although
these data were generated in a healthy mouse model, they provide
support for the continued evaluation of the usefulness of pf-tPA for
the treatment of pulmonary diseases, such as ARDS.
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